Lead Antibody (Pb1): sc-57897

Lead Antibody (Pb1) is a mouse monoclonal IgM antibody that detects Lead protein by enzyme-linked immunosorbent assay (ELISA). Anti-Lead antibody (Pb1) is available as a non-conjugated format, specifically designed to identify and quantify Lead, a soft, heavy, and toxic chemical element with significant implications for human health and the environment. Lead monoclonal antibody (Pb1) detects multiple oxidized forms that can easily revert to metallic state, influencing reactivity and toxicity. Anti-Lead antibody (Pb1) serves as a vital tool for researchers and professionals working to monitor and mitigate Lead exposure effects, particularly given Lead′s ability to cause severe neurological damage and accumulate in soft tissues and bone over time.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Lead Antibody (Pb1) References:

1. Corrosion of lead shielding in a radiology department.  |  Schick, DK., et al. 1999. Australas Radiol. 43: 47-51. PMID: 10901870
2. Lead and the skin.  |  Allen, BR., et al. 1975. Br J Dermatol. 92: 715-9. PMID: 1101941
3. Neurotoxic effect of lead at low concentrations.  |  Mameli, O., et al. 2001. Brain Res Bull. 55: 269-75. PMID: 11470326
4. Extraction of pacemaker and implantable cardioverter defibrillator leads: patient and lead characteristics in relation to the requirement of extraction tools.  |  Bracke, F., et al. 2002. Pacing Clin Electrophysiol. 25: 1037-40. PMID: 12164443
5. Behavioral effects of chronic exposure to low levels of lead in Drosophila melanogaster.  |  Hirsch, HV., et al. 2003. Neurotoxicology. 24: 435-42. PMID: 12782108
6. Molecular targets of lead in brain neurotoxicity.  |  Marchetti, C. 2003. Neurotox Res. 5: 221-36. PMID: 12835126
7. Venous occlusion of the access vein in patients referred for lead extraction: influence of patient and lead characteristics.  |  Bracke, F., et al. 2003. Pacing Clin Electrophysiol. 26: 1649-52. PMID: 12877695
8. Chemical and morphological changes of historical lead objects as a result of the use of electrolytic reduction as a stabilization treatment.  |  Schotte, B., et al. 2006. Anal Chem. 78: 8319-23. PMID: 17165822
9. Lead-interacting proteins and their implication in lead poisoning.  |  de Souza, ID., et al. 2018. Crit Rev Toxicol. 48: 375-386. PMID: 29431551
10. Radiological health implications of lead-210 and polonium-210 accumulations in LPG refineries.  |  Summerlin, J. and Prichard, HM. 1985. Am Ind Hyg Assoc J. 46: 202-5. PMID: 4003271
11. Lead and the kidney: nephropathy, hypertension, and gout.  |  Perazella, MA. 1996. Conn Med. 60: 521-6. PMID: 8908777
12. Selective vulnerability of the developing brain to lead.  |  Johnston, MV. and Goldstein, GW. 1998. Curr Opin Neurol. 11: 689-93. PMID: 9870138